7月31日，康恩贝发布公告称，其全资子公司杭州康恩贝制药有限公司收到国家药监局核准签发的氨甲 环酸片《药品注册证书》。该药品主要用于治疗纤维蛋白溶解亢进所致的各种出血症状。根据公告，该 药品研发投入约627万元，并视同通过仿制药一致性评价。 7月31日，康恩贝主力资金净流出164.35万元，占流通市值的0.01%。 风险提示：药品研发周期长、环节多，容易受到技术、审批、政策等因素影响。 康恩贝7月31日股价报4.65元，较前一交易日下跌0.05元，跌幅1.06%。当日开盘价为4.68元，最高触及 4.72元，最低下探4.64元，成交量为36.7万手，成交金额达1.71亿元。 康恩贝属于医药制造业中的中药板块，公司主要从事药品研发、生产和销售业务。公司产品涵盖中药制 剂、化学原料药及制剂、生物制品等多个领域，拥有完整的医药产业链布局。 ...

一、药品注册证书的主要内容 药品名称：氨甲环酸片 剂型：片剂 证券简称：康恩贝 证券代码：600572 编号：2025-038 浙江康恩贝制药股份有限公司 关于子公司氨甲环酸片获得药品注册证书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其 内容的真实性、准确性和完整性承担法律责任。 近日，浙江康恩贝制药股份有限公司（以下简称"公司""本公司"）全资子公司杭 州康恩贝制药有限公司（以下简称"杭州康恩贝"）收到国家药品监督管理局（以下简称 "国家药监局"）核准签发的规格为 0.25g 的氨甲环酸片《药品注册证书》，现将相关情 况公告如下： 规格：0.25g 注册分类：化学药品 4 类 上市许可持有人：杭州康恩贝 批准文号：国药准字 H20255025 证书编号：2025S02376 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本品符合药品 注册的有关要求，批准注册，发给药品注册证书。 二、该药品研发情况 氨甲环酸片的原研厂家为日本第一三共株式会社，其在日本获批上市的氨甲环酸片有 0.25g 规格和 0.5g 规格，其中 0.5g 规格在中国获批上市 ...

康恩贝（600572）(600572.SH)发布公告，近日，公司全资子公司杭州康恩贝制药有限公司("杭州康恩 贝")收到国家药品监督管理局(以下简称"国家药监局")核准签发的规格为0.25g的氨甲环酸片《药品注册 证书》。 氨甲环酸片的原研厂家为日本第一三共株式会社，其在日本获批上市的氨甲环酸片有0.25g规格和0.5g规 格，其中0.5g规格在中国获批上市。氨甲环酸片主要用于急性或慢性、局限性或全身性原发性纤维蛋白 溶解亢进所致的各种出血;弥散性血管内凝血所致的继发性高纤溶状态。 ...

证券简称：康恩贝 证券代码：600572 编号：2025-037 浙江康恩贝制药股份有限公司 关于子公司培哚普利氨氯地平片（Ⅲ） 获得药品注册证书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其 内容的真实性、准确性和完整性承担法律责任。 注册分类：化学药品 4 类 上市许可持有人：杭州康恩贝 批准文号：国药准字 H20254915 证书编号：2025S02246 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本品符合药品 注册的有关要求，批准注册，发给药品注册证书。 近日，浙江康恩贝制药股份有限公司（以下简称"公司""本公司"）全资子公司杭 州康恩贝制药有限公司（以下简称"杭州康恩贝"）收到国家药品监督管理局（以下简称 "国家药监局"）核准签发的培哚普利氨氯地平片（Ⅲ）《药品注册证书》，现将相关情 况公告如下： 一、药品注册证书的主要内容 药品名称：培哚普利氨氯地平片（Ⅲ） 剂型：片剂 规格：每片含精氨酸培哚普利 10mg、苯磺酸氨氯地平 5mg（按 C₂₀H₂₅N₂O₅Cl 计） 三、其他相关情况 根据国家药监局网站显示，截至本公告日，培哚普利 ...

Buyback Approval and Plan - The board of directors approved a share buyback plan using self-owned funds through centralized bidding on January 23, 2024, with a total fund amount between 200 million yuan and 400 million yuan, and a maximum buyback price of 7 yuan per share [1] Buyback Implementation - The company initiated its first share buyback on January 29, 2024, and completed the buyback by July 21, 2024, acquiring 63.579048 million shares, which is 2.47% of the total share capital at that time. The highest buyback price was 5.00 yuan per share, the lowest was 4.08 yuan, and the average price was 4.72 yuan, with a total expenditure of approximately 299.9241 million yuan [2][3] Use of Funds and Impact - The funds used for the buyback were from the company's own resources and did not significantly impact its daily operations, financial status, or future development. The buyback did not alter the company's control or affect its listing status [3] Shareholder Trading Activity - During the buyback period, company directors, supervisors, and senior management did not trade company shares, except for the controlling shareholder, Zhejiang Pharmaceutical Health Industry Group, which planned to increase its stake by 2% to 4% of the total share capital [3] Change in Buyback Share Purpose - The purpose of the repurchased shares was changed from "for equity incentives" to "for cancellation to reduce registered capital" as approved in board meetings held on April 23 and May 2025 [3] Cancellation of Repurchased Shares - The company announced a notification to creditors regarding the cancellation of repurchased shares, with a creditor declaration period from May 24 to July 7, 2025. No creditors requested early debt repayment or guarantees during this period [5] Post-Cancellation Share Capital Changes - After the cancellation of shares, the total share capital will decrease from 2,585,167,996 shares to 2,521,588,948 shares, reflecting a change in ownership percentages among shareholders [6] Shareholder Ownership Changes - Following the cancellation, the controlling shareholder, Zhejiang Pharmaceutical Health Industry Group, maintained its shareholding at 594,209,740 shares, increasing its ownership percentage from 22.99% to 23.56% [6]

证券代码：600572 证券简称：康恩贝 公告编号：临 2025-036 浙江康恩贝制药股份有限公司 关于注销回购股份实施结果暨股份变动公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对 其内容的真实性、准确性和完整性承担法律责任。 一、回购审批情况和回购方案内容 2024 年 1 月 22 日，浙江康恩贝制药股份有限公司(以下简称"公司")召开第十 届董事会第三十七次（临时）会议，审议通过《关于以集中竞价交易方式回购公司 股份的议案》，并于 2024 年 1 月 23 日在《中国证券报》《上海证券报》《证券时报》 和上海证券交易所网站 www.sse.com.cn（指定信息披露媒体和披露网址下同）披露 了临 2024—006 号《公司关于以集中竞价交易方式回购股份方案的公告》。2024 年 1 月 27 日，公司披露了临 2024—008 号《公司关于以集中竞价交易方式回购股份的回 购报告书》。本次股份回购方案的主要内容如下：同意公司使用自有资金通过上海证 券交易所以集中竞价交易方式回购公司股份，用于实施股权激励。拟回购股份的资 金总额不低于 20,000 万元（含） ...

Core Points - The company announced the results of the stock option incentive plan for the second quarter of 2025, with a total of 492,437 shares exercised [1][8] - The stock option plan was initially approved in September 2022, allowing for the grant of 70 million stock options [1][2] - The exercise price of the stock options was adjusted multiple times, with the latest adjustment setting it at 3.78 yuan per share for the initial grant and 5.07 yuan for reserved options [3][4][5] Summary by Sections Incentive Plan Overview - The stock option incentive plan was approved by the board and supervisory committee in September 2022, with detailed disclosures made on the Shanghai Stock Exchange [1][2] - The plan allows for the grant of stock options to 537 individuals, with a total of 62.475 million options registered [1][2] Adjustments to Exercise Price - The exercise price was adjusted from 4.13 yuan to 3.98 yuan in June 2023 following a cash dividend distribution [2][3] - Further adjustments were made in July 2024, reducing the exercise price to 3.78 yuan for initial options and 5.07 yuan for reserved options [4][5] Exercise Results - As of the second quarter of 2025, a total of 1,486,712.7 shares were exercised, with the total number of shares exercised reaching 49,243.7 shares [6][7] - The shares obtained through the exercise will be tradable two trading days after the exercise date [7] Impact on Share Capital Structure - The total number of shares increased from 2,584,412,009 to 2,584,904,446 after the exercise, with the distribution of shares remaining compliant with listing requirements [7][8] - The company raised 1.844387 million yuan from the exercise of stock options [7]

2025年第二季度，公司本次激励计划激励对象行权且完成股份过户登记的股票 数量合计为49.2437万股。有关情况公告如下： 一、本次激励计划已履行的决策程序及相关信息披露 （一）2022年9月15日，公司十届董事会第二十二次（临时）会议和十届监事会 第十三次（临时）会议分别审议通过了《关于<浙江康恩贝制药股份有限公司2022年 股票期权激励计划（草案）>及摘要的议案》及其他相关议案，公司独立董事、监事 会 、 律师 均 发 表 了相 关 意 见 ，并 于 2022 年9 月 16 日 在 上海 证 券交 易 所 网 站 www.sse.com.cn和《中国证券报》《上海证券报》《证券时报》（以下统称：公司 指定信息披露媒体）进行了详尽披露。（公告编号：临2022-046、临2022-047、临 2022-048） 证券代码：600572 证券简称：康恩贝 公告编号：临2025-035 浙江康恩贝制药股份有限公司 关于2025年第二季度股票期权激励计划 2、本次行权股票上市流通时间：采用自主行权方式行权，激励对象（除公司董事、高级管 理人员外）行权所得股票于行权日（T 日）后的第二个交易日（T+2）日可上市交易 ...

Core Insights - The demand for grape seed health products is increasing due to rising living standards and health awareness among consumers [1][16] - The market size of grape seed health products in China is projected to grow from 5 billion yuan in 2019 to 9 billion yuan by 2024, with a compound annual growth rate of 12% [1][16] - Technological advancements in extraction efficiency and purity are supporting the growth of the grape seed health product market [1][16] Industry Overview - Grape seed health products are derived from grape seeds and contain beneficial components such as vitamins, minerals, amino acids, and antioxidants, offering various health benefits [3][10] - The industry can be categorized by product form (tablets, capsules, liquid), efficacy (antioxidant, anti-aging), and usage scenarios (daily health, beauty, sports nutrition) [5][10] Market Dynamics - The grape seed health product market is experiencing rapid expansion due to the growth of e-commerce and diversified marketing channels [1][16] - The increase in grape production in China, from 13.16 million tons in 2015 to 16.17 million tons in 2023, is expected to provide ample raw materials for grape seed health products [12][14] Regulatory Environment - Recent policies in China aim to promote the integration of the food industry with health and wellness sectors, enhancing the market for functional foods and health products [6][9] Competitive Landscape - Major players in the grape seed health product market include well-known domestic brands such as汤臣倍健 (Tongrentang), 康恩贝 (Kang En Bei), and 九芝堂 (Jiu Zhi Tang), as well as international brands like Nature's Way and NOW Foods [18][19] - Companies are enhancing their competitiveness through improved production technologies and brand marketing strategies [18][19] Consumer Trends - There is a notable increase in consumer demand for high-quality grape seed health products, particularly among women and young adults aged 18 to 35, who represent 83.7% of the health supplement market [24][25] - Consumers are increasingly focused on product quality, efficacy, and safety, necessitating continuous improvement in product formulations [24][25] Future Outlook - The industry is expected to benefit from technological advancements that enhance product absorption and bioavailability [25][26] - The trend of online and offline integration in sales channels is becoming crucial for market growth, providing consumers with a more convenient shopping experience [26][27] - International expansion is a growing trend, with Chinese companies leveraging their resources and technology to compete in global markets [27]

两大区域巨头加强跨境合作，构建更具韧性和可及性的医疗供应链。上海，开罗, June 30, 2025 (GLOBE NEWSWIRE) -- EVA制药公司，作为推动中东和非洲地区医疗创新与可及性的领先制药企业之一，与浙江金华康恩贝生物制药集团，中国最著名的制药集团之一，签署了战略供应协议，标志着全球医疗合作迈出了重要一步。 该协议在2025年中国国际医药原料药展（CPHI China 2025）期间签署，代表了各自地区内两个有影响力企业之间的高层合作。该协议旨在支持更可持续、更灵活和更安全的药品供应链，最终为新兴市场的患者提供更大的可及性。 此次合作反映了两家公司对长期供应可靠性、技术卓越和以患者为中心的交付模式的共同承诺。 “我们正在加强我们对中东和非洲地区患者创新与可及性的承诺。”EVA制药公司首席执行官Riad Armanious表示。“与浙江金华康恩贝的合作为基于信任的跨境供应合作树立了新的标杆，在全球对供应链韧性需求不断增长的背景下。凭借数十年的经验，EVA制药公司已建立了该地区最灵活的制药平台之一，通过深化我们在中国的立足点，我们正在扩大跨境及时、经济高效和高质量治疗的能力。” “作为中国制药 ...